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Abstract 
Background and purpose Vascular risk factors are suboptimally managed 
internationally. This study investigated time trends in risk factors diagnosed 
prior-to-stroke and their treatment, and factors associated with appropriate 
medication use. 
Methods 4416 patients with a first stroke were registered in the population-
based South London Stroke Register from 1995–2011. Previously diagnosed risk 
factors and usual medications were collected from patients’ primary care and 
hospital records. Trends and associations were assessed using multivariate 
logistic regression. 
Results 72% of patients were diagnosed previously with one or more risk factor; 
30% had diagnosed risk factors which were untreated. Hypercholesterolemia 
increased significantly over the study period; MI and TIA prevalences decreased. 
Antiplatelet prescription increased in AF, MI, and TIA (AF: 37%–51%, P<0.001; MI: 
48%–69%, P<0.001; TIA: 49%–61%, P=0.015). Anticoagulant prescription for AF 
showed a non-significant increase (12%–23%; P=0.059). Fewer older patients 
with AF were prescribed anticoagulants (age > 85 v < 65: aRR 0.19, 95% CI 0.08–
0.41). Black ethnicity (aRR 1.17, 95% CI 1.10–1.23) and female sex (aRR 1.09, 95% 
CI 1.03–1.15) were associated with increased antihypertensive drug prescription; 
other medications did not vary by ethnicity or sex. 
Conclusions Antiplatelet and cholesterol-lowering treatment prescribing have 
improved significantly over time; however, only a minority with AF received 
anticoagulants, and this did not improve significantly. Overall, 30% of strokes 
occurred in patients with previously diagnosed but untreated risk factors. 
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Background 
Stroke remains a major preventable cause of morbidity and mortality 
internationally.[1] In addition to lifestyle modification, cost-effective drug 
treatments for hypertension, hypercholesterolemia, and atrial fibrillation (AF) 
reduce stroke risk, heart disease and mortality.[2–4] Despite international 
guidance aimed at improving primary prevention, risk factor control rates remain 
low.[5–7] Suboptimal control is associated with inadequate risk factor detection 
and treatment, ethnic differences in risk factor susceptibility and response to 
treatment, socio-economic deprivation, and poor treatment adherence.[5,7–9] 
Several studies have found ethnic differences in stroke risk factors. A US case-
control study found that hypertension and diabetes were significantly more 
prevalent among black than white stroke patients, whereas AF was significantly 
more prevalent in white patients.[10] Similar results were reported by the South 
London Stroke Register (SLSR) from 1995–98.[11] A US cross-sectional study 
found that apparent ethnic differences in stroke risk factors were explained by 
differences in income.[12] 
We sought to examine trends from 1995–2011 in prior-to-stroke risk factors and 
use of appropriate treatment, using data from the SLSR. We aimed to investigate 
variation in risk factors by age, sex, ethnicity, socio-economic group, and stroke 
subtype, and factors associated with appropriate treatment. 
Methods 
The methods of the SLSR have been described previously,[13] and are 
summarised below. The SLSR is a population-based register recording all first 
strokes in a defined region of Lambeth and Southwark, with a population of 
310,028 according to the 2001 UK Census, with 63% white, 28% black (9% black 
Caribbean, 15% black African, and 4% black other), and 9% other ethnic group. 
By 2011, the source population had increased to 357,308, with 56% white, 25% 
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black (7% black Caribbean, 14% black African, 4% black other) and 18% other. 
The largest increase was in those aged 49–59 (49%); the proportion aged 65+ 
fell by 10%. 
Overlapping notification sources were used to increase data completeness. Data 
were collected by study nurses and field workers. Stroke diagnosis was 
confirmed by a study clinician according to WHO criteria. Ethnicity was self-
reported using 1991 UK census criteria. To increase numbers per group, white 
British and white other were considered as white ethnicity; black Caribbean, 
black African, and black other were grouped as black ethnicity. Risk factors 
recorded prior-to-stroke (hypercholesterolemia [from 2001], hypertension, AF, 
myocardial infarction [MI], transient ischemic attack [TIA], and diabetes) and 
usual prescribed medication (antiplatelets, anticoagulants, antihypertensive 
drugs, and cholesterol-lowering drugs) were collected from patients’ general 
practitioners and hospital records. 
Stroke subtype was determined from CT or MRI results where available and 
classified as ischemic, intracerebral hemorrhage (ICH), subarachnoid 
hemorrhage (SAH), or undefined. Deprivation was estimated using the Carstairs 
index, which combines male unemployment, overcrowding, car ownership and 
proportion in social classes IV and V in a small area.[14] The index was derived 
from 2001 census data for each lower layer super output area (SOA), covering 
an average population of 1500. Scores were obtained from patients’ home 
postcodes at the time of stroke. 
Data were analysed in four-year groups to increase numbers per group. 
Demographic trends were assessed using the Chi-squared test for trends. Risk 
factor and medication trends were assessed in logistic regression models 
adjusting for age, sex, ethnicity, stroke subtype, and deprivation with the year of 
stroke as an explanatory variable. Associations with risk factors and prescribed 
medication were assessed in logistic regression models incorporating sex, age, 
ethnicity, stroke subtype, deprivation, and year of stroke. P values <0.05 were 
regarded as statistically significant. Risk ratios were estimated using  Zhang and 
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Yu’s method.[15] Inter-variable interactions were assessed for each analysis. 
Analyses omitted patients with missing data. Analyses were conducted using 
R.[16] 
Results 
Between January 1995 and 2011, 4416 patients were registered (table 1). Patient 
median age was 72.4 years (interquartile range 61.2–81.1); ethnicities were white 
(70.5%), black (21.3%; 13.0% black Caribbean, 7.6% black African, and 0.6% 
black other), and other (5.7%). Stroke subtypes were ischemic (73.8%), ICH 
(12.7%), SAH (5%), and undefined (8.4%). White and black patients had 
significantly lower Carstairs scores than other ethnicities, but the difference was 
small (mean score [higher=more deprived]: white 9.421, black 9.662, other 10.21; 
P=0.006). Data completeness was high for all variables (ethnicity 97%, stroke 
subtype 96%, risk factors 95–97%; prescribed medication 96–97%). There were 
no significant inter-variable interactions in any analysis. 
Risk factor trends 
Risk factor trends are reported in figure 1 and table 1. 72% of patients had one or 
more risk factors diagnosed prior-to-stroke. Overall risk factor prevalences were: 
hypertension, 64%; hypercholesterolemia, 24%; AF, 16%; diabetes, 19%; prior MI, 
11%; and prior TIA 12%. Hypercholesterolemia significantly increased over time 
(10.5%–31.7%, P<0.001); prior-to-stroke MI and TIA significantly reduced (MI 
7.7%–2.7%, P<0.001; TIA, 16.3%–8.9%, P<0.001).  Hypertension, AF, and diabetes 
did not change significantly over time.  
Risk factor associations 
The multivariate analyses are reported in table 2. Hypertension, diabetes, AF, 
prior MI and TIA increased significantly with age. Hypercholesterolemia was 
highest in those aged 65–74. Hypertension and MI were significantly more 
prevalent in men; other risk factors were not significantly different between men 
and women. 
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Black patients had significantly greater prevalences of hypertension and 
diabetes than white patients (adjusted RRs [aRR]: hypertension 1.22, 95% CI 
1.17–1.27; diabetes 2.15, 95% CI 1.91–2.39) and significantly lower AF, MI, and TIA 
(AF: 0.47, 95% CI 0.35–0.60; MI: 0.58, 95% CI 0.43–0.77; TIA: 0.76, 95% CI 0.59–
0.96). There was no association between deprivation and any risk factor. 
Hypertension prevalence was similar in ischemic stroke and ICH, but significantly 
lower in SAH (aRR v ischemic stroke 0.63, 95% CI 0.52–0.75). 
Hypercholesterolemia, diabetes, prior MI, and AF were significantly less prevalent 
in ICH and SAH than ischemic stroke. 
Prescribing trends 
Trends in prescribed medication are reported in table 1 and figure 2. 26% of 
patients had a single untreated risk factor, 13% had 2 or more. The proportions 
of those with risk factors prescribed appropriate treatment were: hypertension 
62%; hypercholesterolemia 75%; MI (antiplatelets) 62%; AF 64% (anticoagulants 
17%; antiplatelets 48%; [1% both]); TIA (antiplatelets) 58%. Prescribed treatment 
for hypercholesterolemia increased over time (70%–77%, P=0.004). Antiplatelet 
prescription for AF significantly increased (37%–51%, P<0.001); anticoagulant 
prescription increased, but was not significant (12%–23%, P=0.059). Antiplatelet 
prescription in MI and TIA significantly increased over time (MI, 48%–60%, 
P<0.001; TIA, 49%–61%, P=0.015). Antihypertensive prescription did not 
significantly change over time. 
Associations with appropriate treatment 
The multivariate analyses are reported in table 3. Anticoagulant prescription in 
AF for older patients was low, and least in those aged ≥85 (aRRs v <65s; 65–74: 
0.41, 75–84: 0.77, ≥85: 0.19). Significantly more women with hypertension were 
treated than men; there were no significant differences for other risk factor 
treatments between sexes. 
Significantly more black patients with hypertension were treated than white 
patients (aRR 1.17, 95% CI 1.10–1.15). There was no significant association 
between other risk factor treatments and ethnicity, or between deprivation and 
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any risk factor treatment. ICH and SAH were associated with significantly higher 
anticoagulant prescription (aRR v ischemic stroke: ICH 3.14, 95% CI 2.21–4.04; 
SAH 4.64, 95% CI 2.40–5.72). 
Discussion 
This paper analyses trends in the prevalence and treatment of risk factors prior-
to-stroke over 15 years. Hypercholesterolemia increased significantly over time, 
and prior MI and TIA fell. Prescribing of antiplatelets and cholesterol-lowering 
treatments significantly increased over the study period. A minority with AF were 
prescribed anticoagulants; this did not significantly improve over time, and was 
least likely in older people. Overall, one third of first strokes occurred in people 
who were not prescribed treatment for a previously diagnosed risk factor. 
Anticoagulants are effective for the prevention of AF-related stroke; a 2007 
meta-analysis found anticoagulation was substantially more effective than 
aspirin.[17] A UK consensus statement published after the SLSR data were 
collected recommended that aspirin is no longer used for stroke prevention in 
AF.[18] Anticoagulant prescribing for AF remained low throughout the study 
period, and was lowest in older patients, among whom AF was most prevalent. 
UK research found significantly lower primary prevention use among older 
people, despite advancing age being the most important risk factor for vascular 
disease.[19] The SLSR did not record contraindications to anticoagulants, though 
US research found low warfarin use even among those with no 
contraindications.[6] 
These results provide an example of delay in implementing evidence-based 
practice.[20] Guidelines recommending anticoagulation for AF were published in 
the early 1990s.[21] Barriers to anticoagulant use have been examined in 
qualitative research, and include perceived high rates of bleeding, particularly in 
the elderly, and clinicians’ perceptions that patients would not agree to 
treatment.[22] However, an RCT in people aged over 75 found that warfarin was 
more effective than aspirin in preventing stroke, with no increase in 
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hemorrhage.[23] The SLSR data suggest that there is room for improvement in 
the use of anticoagulation in AF. 
Consistent with previous studies,[10] this study found that AF was substantially 
less prevalent in black than white stroke patients. This difference was not 
caused by underdiagnosis: a similar discrepancy was found on ECG on hospital 
admission. This difference may be explained by lower AF prevalence in black 
people in the general population,[24] and ethnic differences in the etiological role 
of AF in stroke.[25] 
RCTs of anticoagulation in AF were conducted overwhelmingly in white 
populations; only 6% of participants were non-white.[25] Additionally, tools for 
identifying AF patients at highest risk, CHADS2 and CHA2DS2-VASc, do not 
incorporate ethnicity and have not been validated in black populations.[26,27] A 
US observational study found increased warfarin-related intracranial hemorrhage 
in black compared with white patients.[28] These data question whether the 
balance of benefit and harm with anticoagulation may vary among different 
ethnic groups.[28] 
Previous studies have found that ethnic minority populations have inadequate 
access to healthcare.[29] We found no difference in risk factor treatment 
between ethnic groups, except for hypertension, with significantly more black 
patients treated than white patients. Here, we did not assess risk factor control, 
but merely whether treatment was prescribed. UK observational studies have 
reported significantly worse control in black compared with white patients.[30, 
31] 
There was a reduction in patients with untreated risk factors from 40% in 1995-
98 to 17% in 1999-2002, followed by increases until 2010, although the overall 
trend was not significant. This change from 1995-98 to 1999-2002 was 
principally caused by a large increase in hypertension treatment from 52-74%. 
This improvement was not sustained; rates reduced to 55% by 2007-10. The 
reason for these changes is unclear, but migration in the source population may 
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have contributed. According to census data, from 1991–2001 the number of black 
African residents increased (7-15%) and the number of white fell (72-63%). 
In the SLSR, deprivation was not associated with significant differences in risk 
factors or prescribed treatments, and was not responsible for ethnic differences 
in risk factors. This contrasts with US research, which reported that income 
differences explained much of the difference in risk factor prevalence between 
white and African American patients.[12] This discrepancy may reflect 
differences in healthcare for deprived populations between the UK and US; US 
research has found inadequate risk factor management was more likely in 
people without health insurance.[32] The reduction in prior MI among first-stroke 
patients is likely to reflect a reduction in MI in the general population; possible 
contributing factors include increasing use of primary prevention and a 2007 UK 
smoking ban in public places.[33] 
Risk factor prevalences are susceptible to changes in diagnostic cutoffs over 
time. UK hypertension guidelines have recommended similar cutoffs over the 
study period (>160/100mmHg, or >140/90 with other risk factors);[34, 35] 
diagnostic criteria for diabetes were lowered in 1999 from a fasting blood 
glucose ≥7.8mmol/l to ≥7.0mmol/l.[36] European guidelines on 
hypercholesterolemia were published in 1998, recommending a diagnostic cutoff 
of total cholesterol ≥5, or LDL cholesterol ≥3;[37] subsequent revisions 
recommend treatment based on overall cardiovascular risk.[38] The large 
increase in hypercholesterolemia is likely to be explained by increased detection. 
Strengths and limitations 
This study was population based, with multiple notification sources including 
hospitalised and community stroke patients. Risk factor diagnoses were 
collected from patient medical records. Though bias may occur through changes 
in documentation practice over the time period, this was mitigated by using both 
hospital and GP records. This study did not collect individual blood pressure or 
serum cholesterol values; therefore, the results represent rates of detected risk 
factors and omit those who were unaware.  
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It is not possible to draw conclusions from this study about primary prevention 
uptake in the general population. The stroke population is more likely to contain 
people with multiple and inadequately treated risk factors. Indeed, the number of 
people with a first stroke reduced over time, which could be consistent with 
improvements in prevention. This study does provide evidence, however, that a 
substantial number of stroke patients were not prescribed optimal treatment for 
previously diagnosed risk factors. 
Conclusions 
There have been significant improvements in the use of appropriate antiplatelet 
and cholesterol-lowering treatments; however, almost one third of strokes 
occurred in patients with diagnosed but untreated risk factors. Anticoagulant 
prescription in AF remained low throughout the study period, and was lowest in 
older people. These results highlight a need for continued research into 
interventions to improve uptake of primary prevention. 
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  1995–1998 1999–2002 2003–2006 2007–2010 P (trend) 
  (n=1305) (n=1074) (n=994) (n=877)  
Sex male 638 (48.9%) 535 (49.8%) 537 (54%) 429 (48.9%) 0.399 
 female 667 (51.1%) 539 (50.2%) 457 (46%) 448 (51.1%) 0.399 
Ethnicity white 1028 (78.8%) 753 (70.1%) 671 (67.5%) 576 (65.7%) <0.001 
 black 216 (16.6%) 209 (19.5%) 221 (22.2%) 225 (25.7%) <0.001 
 other 52 (4%) 62 (5.8%) 73 (7.3%) 57 (6.5%) 0.002 
 unknown 9 (0.7%) 50 (4.7%) 29 (2.9%) 19 (2.2%) 0.058 
Age <65 343 (26.3%) 362 (33.8%) 334 (33.6%) 303 (34.5%) <0.001 
 65–74 365 (28%) 276 (25.7%) 250 (25.2%) 189 (21.6%) 0.001 
 75–84 398 (30.5%) 274 (25.6%) 283 (28.5%) 242 (27.6%) 0.247 
 ≥85 198 (15.2%) 160 (14.9%) 127 (12.8%) 143 (16.3%) 0.954 
Subtype ischemic 916 (70.2%) 786 (73.2%) 776 (78.1%) 699 (79.7%) <0.001 
 ICH 177 (13.6%) 163 (15.2%) 124 (12.5%) 88 (10%) 0.009 
 SAH 71 (5.4%) 71 (6.6%) 51 (5.1%) 20 (2.3%) 0.001 
 undefined 141 (10.8%) 54 (5%) 43 (4.3%) 70 (8%) 0.001 
Risk 
factors 
hypertension 845 (69.2%) 555 (56.8%) 630 (65.1%) 545 (63.4%) 0.091 
 hypercholesterolemia – 97 (10.5%) 226 (23.7%) 272 (31.7%) <0.001 
 diabetes 209 (17%) 178 (18%) 194 (20.3%) 180 (20.7%) 0.166 
 AF 252 (20.6%) 138 (13.9%) 148 (15.3%) 127 (14.9%) 0.13 
 prior MI 90 (7.7%) 37 (4%) 48 (5%) 23 (2.7%) <0.001 
 prior TIA 196 (16.3%) 105 (10.6%) 111 (11.5%) 76 (8.9%) <0.001 
Treatments ≥1 untreated risk 
factor 
524 (40.2%) 184 (17.1%) 236 (23.7%) 311 (35.5%) 0.513 
 treated hypertension  433/827 
(52.4%) 
373/507 
(73.6%) 
460/618 
(74.4%) 
297/540 
(55%) 
0.502 
 treated 
hypercholesterolemia  
– 54/81 (66.7%) 175/223 
(78.5%) 
210/270 
(77.8%) 
0.001 
 AF (antiplatelet) 86/232 
(37.1%) 
52/101 
(51.5%) 
84/147 
(57.1%) 
64/125 
(51.2%) 
<0.001 
 AF (anticoagulant)  30/245 
(12.2%) 
21/124 
(16.9%) 
30/147 
(20.4%) 
29/125 
(23.2%) 
0.059 
 MI (antiplatelet) 75/155 
(48.4%) 
55/77 (71.4%) 74/96 (77.1%) 45/75 (60%) <0.001 
 TIA (antiplatelet) 86/174 
(49.4%) 
56/82 
(68.3%) 
71/111 (64%) 46/75 (61.3%) 0.015 
 TIA (anticoagulant) 6/192 (3.1%) 5/83 (6%) 4/111 (3.6%) 5/75 (6.7%) 0.349 
 
Table 1—Trends in demographics, prior-to-stroke risk factors, and treatments 
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 hypertension hypercholesterolemia diabetes AF prior MI prior TIA 
<65* — — — — — — 
65–74 1.16 (1.1–1.21) 1.39 (1.17–1.63) 1.55 (1.33–1.79) 1.59 (1.27–1.96) 1.7 (1.34–2.15) 1.21 (0.96–
1.52) 
75–84 1.19 (1.14–1.24) 1.11 (0.92–1.33) 1.23 (1.03–
1.45) 
2.35 (1.98–
2.75) 
1.69 (1.33–
2.13) 
1.16 (0.92–
1.45) 
≥85 1.16 (1.1–1.23) 0.78 (0.59–1.01) 0.85 (0.65–
1.09) 
3.04 (2.6–
3.49) 
1.76 (1.32–2.3) 1.21 (0.91–1.58) 
male* — — — — — — 
female 1.05 (1–1.09) 0.99 (0.85–1.14) 0.95 (0.83–
1.08) 
1.1 (0.95–1.27) 0.66 (0.54–
0.8) 
1.07 (0.9–1.27) 
white* — — — — — — 
black 1.22 (1.17–1.27) 0.85 (0.7–1.01) 2.15 (1.91–
2.39) 
0.47 (0.35–
0.6) 
0.58 (0.43–
0.77) 
0.76 (0.59–
0.96) 
other 1.06 (0.96–
1.15) 
1.06 (0.78–1.38) 2.35 (1.96–
2.74) 
0.39 (0.22–
0.63) 
0.77 (0.48–
1.15) 
0.86 (0.56–
1.25) 
unknown 0.89 (0.72–
1.05) 
0.7 (0.37–1.14) 1.75 (1.2–2.36) 1.13 (0.68–1.71) 1.46 (0.84–2.3) 0.71 (0.31–
1.33) 
ischemic* — — — — — — 
ICH 0.95 (0.88–
1.02) 
0.51 (0.36–0.68) 0.55 (0.43–
0.7) 
0.65 (0.49–
0.85) 
0.58 (0.4–0.8) 0.58 (0.41–
0.78) 
SAH 0.63 (0.52–
0.75) 
0.27 (0.12–0.52) 0.23 (0.12–
0.41) 
0.33 (0.14–
0.63) 
0.45 (0.2–
0.83) 
0.08 (0.01–
0.24) 
undefined 0.96 (0.87–
1.04) 
0.95 (0.72–1.21) 1.12 (0.89–
1.38) 
0.91 (0.7–1.17) 1.23 (0.91–1.61) 0.74 (0.51–
1.02) 
5 years 
advance in 
time 
0.97 (0.95–1) 1.51 (1.36–1.66) 1.04 (0.97–1.11) 0.93 (0.86–1) 0.87 (0.79–
0.96) 
0.76 (0.69–
0.84) 
Carstairs 
score (as 
ordinal) 
1.01 (1–1.01) 1 (0.98–1.02) 0.99 (0.97–
1.01) 
0.99 (0.97–
1.01) 
1.03 (1–1.05) 1.02 (1–1.04) 
Table 2—Association of demographics and stroke subtype with risk factors: RRs with 95% CI; 
columns show results from a logistic regression model with the risk factor as the dependent 
variable; *=reference category 
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 hypertension hypercholesterolemia 
MI 
(antiplatelet) 
AF  
(anticoagulant) 
AF  
(antiplatelet) 
TIA 
(antiplatelet) 
<65* — — — — — — 
65–74 1.1 (1.02–1.17) 1.12 (1.03–1.19) 1.04 (0.79–
1.24) 
0.41 (0.2–0.82) 1.12 (0.81–1.42) 1.29 (1.09–1.45) 
75–84 1.05 (0.97–1.13) 1.18 (1.1–1.24) 1.05 (0.81–
1.25) 
0.77 (0.44–1.3) 1.16 (0.87–1.43) 1.18 (0.97–1.36) 
≥85 0.95 (0.84–
1.05) 
1.21 (1.1–1.28) 0.89 (0.6–1.16) 0.19 (0.08–0.41) 1.26 (0.96–
1.53) 
1.28 (1.04–1.46) 
male* — — — — — — 
female 1.09 (1.03–1.15) 0.89 (0.76–0.99) 0.88 (0.71–
1.05) 
1.35 (0.93–1.91) 0.92 (0.75–1.1) 0.94 (0.76–1.11) 
white* — — — — — — 
black 1.17 (1.1–1.23) 0.93 (0.8–1.05) 0.92 (0.66–
1.16) 
0.8 (0.37–1.49) 0.94 (0.65–
1.25) 
0.87 (0.64–1.11) 
other 1.06 (0.92–1.18) 1 (0.8–1.15) 0.7 (0.35–1.11) 1.17 (0.29–2.77) 0.87 (0.37–
1.46) 
1.06 (0.66–1.4) 
unknown 1 (0.76–1.22) not estimable 1.07 (0.6–1.43) 1.5 (0.47–3.11) 0.97 (0.48–
1.48) 
0.39 (0.07–
1.01) 
ischemic* — — — — — — 
ICH 0.79 (0.69–
0.89) 
1.03 (0.82–1.18) 0.68 (0.4–
0.99) 
3.14 (2.21–4.04) 0.45 (0.24–
0.74) 
1.12 (0.8–1.38) 
SAH 0.74 (0.55–
0.93) 
0.85 (0.37–1.21) 0.45 (0.08–
1.11) 
4.64 (2.4–5.72) 0.3 (0.02–1.06) not estimable 
undefined 0.83 (0.72–
0.95) 
1.08 (0.91–1.21) 1.04 (0.78–
1.26) 
0.71 (0.28–1.41) 1.19 (0.9–1.46) 1.14 (0.8–1.42) 
5 years advance in 
time 
1.01 (0.98–1.04) 1.09 (1.03–1.15) 1.15 (1.07–1.22) 1.21 (1.01–1.45) 1.18 (1.09–1.26) 1.11 (1.03–1.19) 
Carstairs score (as 
ordinal) 
1 (0.99–1.01) 1 (0.99–1.02) 1 (0.98–1.02) 0.98 (0.94–1.03) 1 (0.98–1.02) 0.99 (0.97–
1.01) 
Table 3—Association of demographics and stroke subtype with prescribed preventative 
medication: RRs with 95% CI; columns show results from a logistic regression model with the 
risk factor as the dependent variable; *=reference category 
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